3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Discrepancies between radiological and histological findings in preoperative core needle (CNB) and vacuum-assisted (VAB) breast biopsies

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Ultrasound (US)-guided breast biopsy is a routine diagnostic method used to correlate imaging finding to a histological diagnosis which is still the gold standard in preoperative diagnostics. The accuracy of US-guided breast biopsies relies on a precise radiologic-histopathologic correlation, which is discussed amongst an interdisciplinary team of gynecologists, radiologists and pathologists. However, false-negative or non-diagnostic biopsy results occur. Hence, a thorough and honest discussion to clarify the reason for discrepancies and to decide the next diagnostic step between specialists of the different disciplines is warranted. In this retrospective study, we analyzed discrepant findings between imaging and pathology results on preoperative breast biopsies.

          Methods

          Core and vacuum-assisted breast biopsies from 232 patients were included in this study. Inclusion criteria were (1) non-diagnostic (B1) category on histology independent from imaging category and (2) histological benign (B2) category with a BIRADS 5 (Breast Imaging Reporting and Data System) rating on imaging. Histological diagnoses were retrieved from all cases. Follow-up data were available in most cases.

          Results

          138 biopsies were classified as B1, 94 biopsies as B2 category. 51 of 138 B1 cases (37%) underwent re-biopsy. Re-biopsy found malignancy (B5) in 19 of 51 cases, and B3/4 (premalignant) lesions in 3 of 51 cases. All B2 cases underwent second-look imaging-diagnosis, in 57 of 94 cases (66%) consecutive direct surgery or re-biopsy. Of these, malignancy was diagnosed histologically in 26 of 57 cases (45.6%).

          Conclusion

          Determining imaging-pathology concordance after US-guided breast biopsy is essential. Discrepant cases and further diagnostic steps need to be discussed with an interdisciplinary approach.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Observer variability of Breast Imaging Reporting and Data System (BI-RADS) for breast ultrasound.

          To evaluate inter- and intra-observer variabilities in breast sonographic feature analysis and management, using the fourth edition of the Breast Imaging Reporting and Data System (BI-RADS). We included 136 patients with 150 breast lesions who underwent breast ultrasound (US) and ultrasound-guided core needle biopsy. A pathological diagnosis was available for all 150 lesions: 77 (51%) malignant and 73 (49%) benign. Four radiologists retrospectively reviewed sonographic images of lesions twice within an 8-week interval. The observers described each lesion, using BI-RADS descriptors and final assessment. Inter- and intra-observer variabilities were assessed with Cohen's kappa statistic. Positive predictive value and negative predictive value (NPV) for final assessment were also calculated. For inter-observer agreements for sonographic descriptors, substantial agreement for lesion calcification and final assessment (kappa=0.61 for both), moderate agreement for lesion shape, orientation, boundary, and posterior acoustic features (kappa=0.49, 0.56, 0.59, and 0.49, respectively), and fair agreement for lesion margin and echo pattern (kappa=0.33 and 0.37, respectively) were obtained. For intra-observer agreement, substantial to perfect agreement was found for almost all lesion descriptors and final assessments. NPV for final assessment category 3 was 95%. Positive predictive value (PPV) for final assessment categorized as 4 or 5 were as follows: category 4a, 26%; category 4b, 89%; category 4c, 90%; and category 5, 97%. Because inter- and intra-observer agreement with the BI-RADS lexicon for US is good, the use of BI-RADS lexicon can provide accurate and consistent description and assessment for breast US.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical application of the BI-RADS final assessment to breast sonography in conjunction with mammography.

            The objective of our study was to report the results of classification of sonographic findings according to BI-RADS and to calculate the positive predictive value (PPV) for each BI-RADS assessment category. We prospectively classified 4,668 breast sonograms according to BI-RADS final assessment category. Suspicious sonographic findings were divided into major and minor suspicious findings. Category 1 was normal and category 2 was a benign finding such as cyst or nodule with uniform and intense hyperechogenicity. A nodule neither category 2 nor category 4 or 5 was defined as category 3. A nodule with one or more suspicious findings, not category 5, was defined as category 4. A nodule with two or more major suspicious findings was defined as category 5. Of the 4,668 cases, 321 cases failed to undergo follow-up of at least 1 year. The PPV was 0.1% in category 1 (3/2,191), 0% in category 2 (0/773), 0.8% in category 3 (6/737), 31.1% in category 4 (161/519), and 96.9% in category 5 (123/127). In palpable lesions (n = 751), the PPV was 2.2% in category 1 (2/93), 0.9% in category 3 (2/217), 54% in category 4 (107/198), and 98% in category 5 (98/100). In nonpalpable lesions (n = 3,596), the PPV was 0.05% in category 1 (1/2,098), 0.8% in category 3 (4/520), 16.8% in category 4 (54/321), and 92.6% in category 5 (25/27). As with mammography, placing sonographic lesions into BI-RADS categories is useful for predicting the presence of malignancy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Missed breast cancers at US-guided core needle biopsy: how to reduce them.

              Ultrasonographically (US) guided core needle biopsy is currently recognized as a reliable alternative to surgical biopsy for the histopathologic diagnosis of breast lesions. However, despite advances in biopsy devices and techniques, false-negative diagnoses are unavoidable and may delay the diagnosis and treatment of breast cancer. The most common reasons for false-negative diagnosis are (a) technical or sampling errors, (b) failure to recognize or act on radiologic-histologic discordance, and (c) lack of imaging follow-up after a benign biopsy result. Technical difficulties (eg, poor lesion or needle visualization, deeply located lesions, dense fibrotic tissue) cause inaccurate sampling but can be reduced by using modified standard techniques. Radiologic-histologic correlation is also of critical importance in US-guided core needle biopsy. Radiologic-histologic discordance occurs when the histologic results do not provide a sufficient explanation for the imaging features and indicates that the lesion may not have been sampled adequately, so that repeat biopsy is warranted. Appropriate follow-up imaging is invaluable; even patients with concordant benign findings after US-guided core needle biopsy are directed to undergo follow-up imaging because there may be delays in the recognition of false-negative findings. Optimization of technique, radiologic-histologic correlation, and postbiopsy follow-up protocols are recommended to reduce the occurrence of false-negative diagnosis at US-guided core needle biopsy performed by radiologists. Copyright RSNA, 2007.
                Bookmark

                Author and article information

                Contributors
                zsuzsanna.varga@usz.ch
                Journal
                J Cancer Res Clin Oncol
                J Cancer Res Clin Oncol
                Journal of Cancer Research and Clinical Oncology
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0171-5216
                1432-1335
                7 December 2020
                7 December 2020
                2021
                : 147
                : 3
                : 749-754
                Affiliations
                [1 ]Department of Gynecology, Hospital Triemli, Zurich, Switzerland
                [2 ]GRID grid.412004.3, ISNI 0000 0004 0478 9977, Institute of Diagnostic Radiology, , University Hospital Zurich, ; Zurich, Switzerland
                [3 ]GRID grid.476941.9, Breast Center Seefeld, ; Zurich, Switzerland
                [4 ]GRID grid.412581.b, ISNI 0000 0000 9024 6397, Department of Radiology, , University Witten-Herdecke, ; Witten, Germany
                [5 ]Department of Gynecology, Hospital Zollikerberg, Zollikerberg, Switzerland
                [6 ]Department of Gynecology, Hospital Männedorf, Zurich, Switzerland
                [7 ]GRID grid.412004.3, ISNI 0000 0004 0478 9977, Breast Center, , University Hospital Zurich, ; Zurich, Switzerland
                [8 ]GRID grid.412004.3, ISNI 0000 0004 0478 9977, Comprehensive Cancer Center Zurich, , University Hospital Zurich, ; Zurich, Switzerland
                [9 ]GRID grid.412004.3, ISNI 0000 0004 0478 9977, Institute of Pathology and Molecular Pathology, , University Hospital Zurich, ; Schmelzbergstrasse 12, 8091 Zurich, Switzerland
                Author information
                http://orcid.org/0000-0002-2855-983X
                Article
                3481
                10.1007/s00432-020-03481-7
                7873108
                33284380
                b49928e1-a8b9-4972-9792-3931e83a69fb
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 27 July 2020
                : 22 November 2020
                Funding
                Funded by: University of Zurich
                Categories
                Original Article – Cancer Research
                Custom metadata
                © Springer-Verlag GmbH Germany, part of Springer Nature 2021

                Oncology & Radiotherapy
                breast biopsy,discrepancy,imaging,histology
                Oncology & Radiotherapy
                breast biopsy, discrepancy, imaging, histology

                Comments

                Comment on this article